View Older Stories View More Recent Stories

Jan 18, 2019 07:00AM Kyn Therapeutics Enters into Global Strategic Collaboration with Celgene to Develop Immuno-oncology Therapies
Jan 3, 2019 08:00AM Nimbus Therapeutics Strengthens Leadership Team
Jan 2, 2019 01:47PM Form D/A Atlas Venture Opportunit
Jan 2, 2019 06:50AM Atlas Venture Announces $250 Million Opportunity Fund
Dec 17, 2018 09:05AM Generation Bio to Appoint Tom Graney as Chief Financial Officer
Dec 12, 2018 07:00AM Akero Therapeutics Announces $70 Million in New Financing to Advance Therapeutic Pipeline for NASH, Serious Metabolic Diseases
Dec 6, 2018 08:00AM Akero Therapeutics Appoints Mark Iwicki to its Board of Directors
Dec 6, 2018 05:56AM miRagen Therapeutics (MGEN) Appoints Jeff Hatfield to Succeed Dr. Bruce Booth as New Board Chairman
Dec 5, 2018 04:05PM miRagen Therapeutics Announces Board of Director Evolution and Appointment of New Chairman
Nov 29, 2018 10:56AM Form D Atlas Venture Opportunit
Nov 29, 2018 07:00AM Successful Seven-figure Funding Round for Provider of SaaS Customer Loyalty Platform: Loyalty Prime Intensifies Its International Growth
Nov 27, 2018 08:00AM Biotech Showcase™ Highlights Six Therapeutic Areas Garnering Attention for Investment in 2019
Nov 19, 2018 12:24PM Applied BioMath, LLC Announces Collaboration with Obsidian Therapeutics for Semi-Mechanistic Quantitative Modeling of a Novel Therapeutic Platform
Nov 19, 2018 07:00AM Generation Bio to Present at the Evercore ISI Healthcare Conference
Nov 15, 2018 06:00AM Saniona’s partner Cadent Therapeutics initiates Phase 2 for CAD-1883 and secures USD 40 million financing
Nov 15, 2018 06:00AM Cadent Therapeutics Secures $40 Million Series B Financing to Advance Pipeline of Novel Therapies for Movement and Cognitive Disorders
Nov 13, 2018 07:00AM Kymera Therapeutics Announces $65 Million Series B Financing to Advance Pipeline of Targeted Protein Degraders in Oncology and Immunology
Nov 9, 2018 08:30AM Obsidian Presents Preclinical Data Demonstrating Precise Regulation of Cytokines and CAR in T cells with Destabilizing Domain Technology using FDA-Approved Drugs
Nov 7, 2018 10:20AM Form 13F-HR Atlas Venture Associates For: Sep 30
Nov 5, 2018 08:00AM Generation Bio Appoints Antoinette Paone as Head of Regulatory Affairs
Nov 3, 2018 09:00AM Disarm Therapeutics Presents New Data Validating Role of SARM1 in Axonal Degeneration
Oct 30, 2018 08:00AM HotSpot Therapeutics Expands Board of Directors and Management Team
Oct 25, 2018 06:00AM Disarm Therapeutics Appoints Industry Leaders Robert Copeland, PhD, and Kimi Iguchi, CPA, to Board of Directors
Oct 17, 2018 08:00AM Akero Therapeutics Expands Leadership Team
Oct 4, 2018 08:00AM Generation Bio Appoints Dr. Richard Thompson to its Scientific Advisory Board
Sep 27, 2018 07:30AM Akrevia Therapeutics Launches with $30M Series A Financing Led by F-Prime Capital Partners and Atlas Venture
Sep 17, 2018 03:00AM Virion Appoints Vanessa King as President & CEO and Isabel Najera as CSO
Sep 11, 2018 07:00AM Andrew Cheng, MD, PhD Joins Akero Therapeutics as President and Chief Executive Officer
Aug 2, 2018 04:30PM Navitor Pharmaceuticals Appoints Thomas E. Hughes, Ph.D. as Chief Executive Officer
Jul 31, 2018 08:00AM Generation Bio Appoints Charles Rowland to its Board of Directors
Jul 31, 2018 06:46AM Form 13F-HR Atlas Venture Associates For: Jun 30
Jul 27, 2018 08:00AM Life Science Executives and Investors Connect with Biotech Startups at BioPharm America™ Global Partnering Event this September
Jul 26, 2018 05:26PM Form 4 Replimune Group, Inc. For: Jul 24 Filed by: Atlas Venture Associates X, LLC
Jul 23, 2018 07:00AM Disarm Therapeutics Presents Data Demonstrating the Protective Effect of SARM1 Deletion on Axonal Degeneration
Jul 19, 2018 09:19PM Form 3 Replimune Group, Inc. For: Jul 19 Filed by: Atlas Venture Fund X, L.P.
Jul 19, 2018 07:30AM IFM Therapeutics, LLC Launches Subsidiary, IFM Tre, with $31 Million Series A Financing to Develop NLRP3 Antagonists for Inflammatory Diseases
Jul 17, 2018 07:00AM HotSpot Therapeutics Completes $45 Million Series A Financing to Advance New Approach to Allosteric Drug Discovery
Jul 3, 2018 06:45PM Form 4 Translate Bio, Inc. For: Jul 02 Filed by: Atlas Venture Fund VIII, L.P.
Jul 2, 2018 04:02PM Form 4 ZAFGEN, INC. For: Jun 29 Filed by: Atlas Venture Associates VII, L.P.
Jun 27, 2018 06:34PM Form 3 Translate Bio, Inc. For: Jun 27 Filed by: Atlas Venture Associates VIII, L.P.
Jun 27, 2018 04:37PM Form 4 Magenta Therapeutics, For: Jun 25 Filed by: ATLAS VENTURE ASSOCIATES X, L.P.
Jun 25, 2018 06:23PM Form 4 AVROBIO, Inc. For: Jun 25 Filed by: ATLAS VENTURE ASSOCIATES X, L.P.
Jun 25, 2018 07:00AM Akero Therapeutics Closes $65 Million Series A Financing to Advance New Treatments for Serious Metabolic Diseases
Jun 20, 2018 08:45PM Form 3 Magenta Therapeutics, For: Jun 20 Filed by: Atlas Venture Fund X, L.P.
Jun 20, 2018 08:07PM Form 3 AVROBIO, Inc. For: Jun 20 Filed by: Atlas Venture Fund X, L.P.
Jun 7, 2018 08:00AM Generation Bio Appoints Jeff Jonas M.D. to its Board of Directors
Jun 5, 2018 07:00AM Atlas Venture Announces Andrea Armstrong Joins as Chief Talent Officer
May 31, 2018 11:53AM Harvard Business School Names 2018-2019 Blavatnik Fellows in Life Science Entrepreneurship
May 31, 2018 07:00AM BioPharm America™ Once Again Offers Top Quality Opportunities for Networking with Global Life Science Executives This September
May 18, 2018 05:00AM Accent Therapeutics Announces Company Launch with $40 Million Series A Financing for Novel, Precision Cancer Treatments Targeting RNA-Modifying Proteins
View More Recent Stories View Older Stories